Login / Signup

Susceptibility of β-Thalassemia Heterozygotes to COVID-19.

Sotirios SotiriouAthina A SamaraDimitra VamvakopoulouKonstantinos-Odysseas VamvakopoulosAndreas SidiropoulosNikolaos VamvakopoulosMichel B JanhoKonstantinos I GourgoulianisStyllianos Boutlas
Published in: Journal of clinical medicine (2021)
Our pilot observations indicate enhanced mortality of β-thalassemia heterozygotes from COVID-19.
Keyphrases
  • coronavirus disease
  • sars cov
  • sickle cell disease
  • cardiovascular events
  • respiratory syndrome coronavirus
  • randomized controlled trial
  • cardiovascular disease
  • clinical trial
  • type diabetes
  • coronary artery disease